Glycosylation and its implications in breast cancer

References

• Aub JC, Tieslau C, Lankester A. Reactions of normal and tumor cell surfaces to enzymes. i. wheat-germ lipase and associated mucopolysaccharides. Proc Natl Acad Sci U S A. 1963 Oct;50:613–619. PubMed PMID: 14077487; PubMed Central PMCID: PMCPMC221235. eng.
   PubMed Web of Science ®Google Scholar
• Barton JG, Bois JP, Sarr MG, et al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg. 2009 Nov;13(11):2050–2058. PubMed PMID: 19756875; eng.
   PubMed Web of Science ®Google Scholar
• Drake RR. Glycosylation and cancer: moving glycomics to the forefront. Adv Cancer Res. 2015;126:1–10.
   PubMed Web of Science ®Google Scholar
• Kirwan A, Utratna M, O’Dwyer ME, et al. Glycosylation-based serum biomarkers for cancer diagnostics and prognostics. Biomed Res Int. 2015 Oct 05;2015: 490531. 04/02/received 05/28/revised 05/31/accepted. PubMed PMID: PMC4609776.
   PubMed Web of Science ®Google Scholar
• Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005 Nov;5(11):845–856. PubMed PMID: 16239904; eng.
   PubMed Web of Science ®Google Scholar
• Sawyers CL. The cancer biomarker problem. Nature. 2008 Apr 02;452:548. online.
   PubMed Web of Science ®Google Scholar
• Song E, Mechref Y. Defining glycoprotein cancer biomarkers by MS in conjunction with glycoprotein enrichment. Biomark Med. 2015 Sep 02;9(9):835–844. PubMed PMID: PMC4889013.
   PubMed Web of Science ®Google Scholar
• Grishman E. Histochemical analysis of mucopolysaccharides occurring in mucus-producing tumors; mixed tumors of the parotid gland, colloid carcinomas of the breast, and myxomas. Cancer. 1952 Jul;5(4):700–707. PubMed PMID: 14935980; eng.
   PubMed Web of Science ®Google Scholar
• Remmele W, Hildebrand U, Hienz HA, et al. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127–147. PubMed PMID: 2424168; eng.
   PubMedGoogle Scholar
• Parodi AJ, Blank EW, Peterson JA, et al. Dolichol-bound oligosaccharides and the transfer of distal monosaccharides in the synthesis of glycoproteins by normal and tumor mammary epithelial cells. Breast Cancer Res Treat. 1982;2(3):227–237. PubMed PMID: 6817834; eng.
   PubMedGoogle Scholar
• Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature. 1985 Mar 7–13;314(6006):53–57. PubMed PMID: 2579340; eng.
   PubMed Web of Science ®Google Scholar
• Desai PR. Immunoreactive T and Tn antigens in malignancy: role in carcinoma diagnosis, prognosis, and immunotherapy. Transfus Med Rev. 2000 Oct;14(4):312–325. PubMed PMID: 11055076; eng.
   PubMed Web of Science ®Google Scholar
• Foster CS, Neville AM. Expression of breast epithelial differentiation antigens in human primary breast cancer. J Natl Cancer Inst. 1987 Oct;79(4):613–622. PubMed PMID: 2443736; eng.
   PubMedGoogle Scholar
• Kirmiz C, Li B, An HJ, et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics. 2007 Jan 1;6(1):43–55.
   PubMed Web of Science ®Google Scholar
• Wolf MF, Ludwig A, Fritz P, et al. Increased expression of Thomsen-Friedenreich antigens during tumor progression in breast cancer patients. Tumour Biol. 1988;9(4):190–194. PubMed PMID: 3420374; eng.
   PubMedGoogle Scholar
• Burchell J, Durbin H, Taylor-Papadimitriou J. Complexity of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells. J Immunol. 1983 Jul;131(1):508–513. PubMed PMID: 6190927; eng.
   PubMed Web of Science ®Google Scholar
• Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med (Berl). 1997 Aug;75(8):594–602. PubMed PMID: 9297627; eng.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 2010 Dec 14;411(23–24):1869–1874. PubMed PMID: 20816948; eng.
   PubMed Web of Science ®Google Scholar
• Lin S, Kemmner W, Grigull S, et al. Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells. Exp Cell Res. 2002 May 15;276(1):101–110. PubMed PMID: 11978012; eng.
   PubMed Web of Science ®Google Scholar
• Abd Hamid UM, Royle L, Saldova R, et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology. 2008;18(12):1105–1118.
   PubMed Web of Science ®Google Scholar
• Scott DA, Casadonte R, Cardinali B, et al. Increases in tumor N-glycan polylactosamines associated with advanced HER2 positive and triple negative breast cancer tissues. Proteomics Clin Appl. 2018 Dec 28;e1800014. PubMed PMID: 30592377; eng. DOI:10.1002/prca.201800014
   Web of Science ®Google Scholar
• Scott DA, Norris-Caneda K, Spruill L, et al. Specific N-linked glycosylation patterns in areas of necrosis in tumor tissues. Int J Mass Spectrom. 2018;437:69–76.
   PubMed Web of Science ®Google Scholar
• Howlader NNA, Krapcho M, Miller D, et al. (eds). SEER cancer statistics review, 1975–2014. In: Institute NC, editor. SEER website 2016.
   Google Scholar
• Ibrahim E, Al-Gahmi AM, Zeenelin AA, et al. Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers. Med Oncol. 2009;26(3):372–378. PubMed PMID: 19034706; eng.
   PubMed Web of Science ®Google Scholar
• Cancer stat facts: female breast cancer. In: Surveillance EaERP, editor. Online: National Cancer Institute; 2019.
   Google Scholar
• The Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumors. Nature. 2012 Sep 23;490(7418):61–70. PubMed PMID: PMC3465532.
   PubMed Web of Science ®Google Scholar
• Peiris D, Spector AF, Lomax-Browne H, et al. Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors [Article]. Sci Rep. 2017 Feb 22;7:43006. online. https://www.nature.com/articles/srep43006#supplementary-information
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11;363(20):1938–1948. PubMed PMID: 21067385; eng.
   PubMed Web of Science ®Google Scholar
• Yu T, Di G. Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. Chin J Cancer Res. 2017;29(3):237–252. 01/20/received 04/12/accepted. PubMed PMID: PMC5497211.
   PubMed Web of Science ®Google Scholar
• Liao HY, Zhang WW, Sun JY, et al. The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer. J Cancer. 2018;9(2):296–303. PubMed PMID: 29344276; PubMed Central PMCID: PMCPMC5771337. eng.
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene. 2007;26. DOI:10.1038/sj.onc.1210379
   Web of Science ®Google Scholar
• Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23. DOI:10.1200/jco.2005.16.584
   Google Scholar
• Lauc G, Pezer M, Rudan I, et al. Mechanisms of disease: the human N-glycome. Biochim Biophys Acta. 2016 Aug;1860(8):1574–1582. PubMed PMID: 26500099; eng.
   PubMed Web of Science ®Google Scholar
• Eccles SA, Aboagye EO, Ali S, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. BCR. 2013;15(5):R92–R92. PubMed PMID: 24286369.
   PubMed Web of Science ®Google Scholar
• Fallahpour S, Navaneelan T, De P, et al. Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open. 2017 Jul-Sep 09/25;5(3):E734–E739. PubMed PMID: PMC5621954.
   PubMedGoogle Scholar
• Noone AMHN, Krapcho M, Miller D, et al. (eds). SEER cancer statistics review (National Cancer Institute). based on November 2017 SEER data submission, posted to SEER website April 2018. 2017.
   Google Scholar
• Network NCC.. NCCN clinical practice guidelines in oncology. NCCN; 2018 March 20.
   Google Scholar
• Polyak K. Breast cancer: origins and evolution. J Clin Invest. 2007 Nov 01;117(11):3155–3163.
   PubMed Web of Science ®Google Scholar
• Kleibl Z, Kristensen VN. Women at high risk of breast cancer: molecular characteristics, clinical presentation and management. Breast. 2016 Aug 01;28:136–144.
   PubMed Web of Science ®Google Scholar
• Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int. 2013;2013:747318. PubMed PMID: 23586058.
   PubMed Web of Science ®Google Scholar
• Simpson PT, Reis‐Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol. 2005;205(2):248–254.
   PubMed Web of Science ®Google Scholar
• Varki A. Biological roles of glycans. Glycobiology. 2017 Jan;27(1):3–49. PubMed PMID: 27558841; PubMed Central PMCID: PMCPMC5884436. eng.
   PubMed Web of Science ®Google Scholar
• Dennis JW, Lau KS, Demetriou M, et al. Adaptive regulation at the cell surface by n-glycosylation. Traffic. 2009;10(11):1569–1578.
   PubMed Web of Science ®Google Scholar
• Ohtsubo K, Takamatsu S, Minowa MT, et al. Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell. 2005 Dec 29;123(7):1307–1321.
   PubMed Web of Science ®Google Scholar
• Partridge EA, Le Roy C, Di Guglielmo GM, et al. Regulation of cytokine receptors by Golgi N-Glycan processing and endocytosis. Science. 2004;306(5693):120–124.
   PubMed Web of Science ®Google Scholar
• Schachter H. The search for glycan function: fucosylation of the TGF-β1 receptor is required for receptor activation. Proc Natl Acad Sci U S A. 2005;102(44):15721–15722.
   PubMed Web of Science ®Google Scholar
• Liu YC, Yen HY, Chen CY, et al. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11332–11337. PubMed PMID: 21709263; PubMed Central PMCID: PMCPMC3136320. eng.
   PubMed Web of Science ®Google Scholar
• Lo WY, Lagrange AH, Hernandez CC, et al. Glycosylation of {beta}2 subunits regulates GABAA receptor biogenesis and channel gating. J Biol Chem. 2010 Oct 8;285(41):31348–31361. PubMed PMID: 20639197; PubMed Central PMCID: PMCPMC2951209. eng.
   PubMed Web of Science ®Google Scholar
• Munkley J, Elliott DJ. Hallmarks of glycosylation in cancer. Oncotarget. 2016 Mar 17;7(23):35478–35489. 01/28/received 03/02/accepted. PubMed PMID: PMC5085245.
   PubMed Web of Science ®Google Scholar
• Kuzmanov U, Kosanam H, Diamandis EP. The sweet and sour of serological glycoprotein tumor biomarker quantification. BMC Med. 2013 Feb 07;11:31. PubMed PMID: 23390961; PubMed Central PMCID: PMCPMC3751898. eng.
   PubMed Web of Science ®Google Scholar
• Spiro RG. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology. 2002 Apr;12(4):43r–56r. PubMed PMID: 12042244; eng.
   PubMed Web of Science ®Google Scholar
• Potapenko IO, Haakensen VD, Luders T, et al. Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol Oncol. 2010 Apr;4(2):98–118. PubMed PMID: 20060370; eng.
   PubMed Web of Science ®Google Scholar
• Varki A, Cummings RD, Esko JD, et al., editors. Essentials of glycobiology. 3 ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2017.
   Google Scholar
• Abbott KL, Aoki K, Lim J-M, et al. Targeted glycoproteomic identification of biomarkers for human breast carcinoma. J Proteome Res. 2008 Apr 01;7(4):1470–1480.
   PubMed Web of Science ®Google Scholar
• Ladenson RP, Schwartz SO, Ivy AC. Incidence of the blood groups and the secretor factor in patients with pernicious anemia and stomach carcinoma. Am J Med Sci. 1949 Feb;217(2):194–197. PubMed PMID: 18109280; eng.
   PubMed Web of Science ®Google Scholar
• Taniguchi N, Kizuka Y. Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. Adv Cancer Res. 2015;126:11–51. PubMed PMID: 25727145; eng.
   PubMed Web of Science ®Google Scholar
• Blanas A, Sahasrabudhe NM, Rodríguez E, et al. Fucosylated antigens in cancer: an alliance toward tumor progression, metastasis, and resistance to chemotherapy. Front Oncol. 2018 Feb 23;8:39. 11/29/received 02/05/accepted. PubMed PMID: PMC5829055.
   PubMed Web of Science ®Google Scholar
• Burchell JM, Beatson R, Graham R, et al. O-linked mucin-type glycosylation in breast cancer. Biochem Soc Trans. 2018;46:779–788.
   PubMed Web of Science ®Google Scholar
• Cui H, Lin Y, Yue L, et al. Differential expression of the alpha2,3-sialic acid residues in breast cancer is associated with metastatic potential. Oncol Rep. 2011 May;25(5):1365–1371. PubMed PMID: 21344161; eng.
   PubMed Web of Science ®Google Scholar
• Josic D, Martinovic T, Pavelic K. Glycosylation and metastases. Electrophoresis. 2018 Sep 24. PubMed PMID: 30246896; eng. DOI:10.1002/elps.201800238
   Web of Science ®Google Scholar
• Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J. 1997 Aug;14(5):569–576. PubMed PMID: 9298689; eng.
   PubMed Web of Science ®Google Scholar
• Liu X, Nie H, Zhang Y, et al. Cell surface-specific N-glycan profiling in breast cancer. PloS One. 2013;8(8):e72704. PubMed PMID: 24009699; PubMed Central PMCID: PMCPMC3751845. eng.
   PubMed Web of Science ®Google Scholar
• Ray MRJ, David M. Hallmarks of metastasis. Lung Cancer Metastasis. 2009;29–46.
   Google Scholar
• Rodrigues JG, Balmaña M, Macedo JA, et al. Glycosylation in cancer: selected roles in tumour progression, immune modulation and metastasis. Cell Immunol. 2018;333:46–57.
   PubMed Web of Science ®Google Scholar
• Hakomori S, Kannagi R. Glycosphingolipids as tumor-associated and differentiation markers. J Natl Cancer Inst. 1983 Aug;71(2):231–251. PubMed PMID: 6576183; eng.
   PubMedGoogle Scholar
• Kannagi R, Yin J, Miyazaki K, et al. Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants–hakomori’s concepts revisited. Biochim Biophys Acta. 2008 Mar;1780(3):525–531. PubMed PMID: 17980710; eng.
   PubMed Web of Science ®Google Scholar
• Drake RR, West CA, Mehta AS, et al. MALDI mass spectrometry imaging of N-linked glycans in tissues. Adv Exp Med Biol. 2018;59–76.
   PubMed Web of Science ®Google Scholar
• Buckhaults P, Chen L, Fregien N, et al. Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene. J Biol Chem. 1997 Aug 1;272(31):19575–19581. PubMed PMID: 9235963; eng.
   PubMed Web of Science ®Google Scholar
• Hatano K, Miyamoto Y, Nonomura N, et al. Expression of gangliosides, GD1a, and sialyl paragloboside is regulated by NF-kappaB-dependent transcriptional control of alpha2,3-sialyltransferase I, II, and VI in human castration-resistant prostate cancer cells. Int J Cancer. 2011 Oct 15;129(8):1838–1847. PubMed PMID: 21165949; eng.
   PubMed Web of Science ®Google Scholar
• Kumamoto K, Goto Y, Sekikawa K, et al. Increased expression of UDP-galactose transporter messenger RNA in human colon cancer tissues and its implication in synthesis of Thomsen-Friedenreich antigen and sialyl Lewis A/X determinants. Cancer Res. 2001 Jun 1;61(11):4620–4627. PubMed PMID: 11389099; eng.
   PubMed Web of Science ®Google Scholar
• Pinho SS, Oliveira P, Cabral J, et al. Loss and recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions. PloS One. 2012;7(3):e33191. PubMed PMID: 22427986; PubMed Central PMCID: PMCPMC3302839. eng.
   PubMed Web of Science ®Google Scholar
• Arnold JN, Saldova R, Hamid UM, et al. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics. 2008 Aug;8(16):3284–3293. PubMed PMID: 18646009; eng.
   PubMed Web of Science ®Google Scholar
• Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231–10233. PubMed PMID: 12149519; PubMed Central PMCID: PMCPMC124893. eng.
   PubMed Web of Science ®Google Scholar
• Drake RR, Jones EE, Powers TW, et al. Altered glycosylation in prostate cancer. Adv Cancer Res. 2015;126:345–382. PubMed PMID: 25727153; eng.
   PubMed Web of Science ®Google Scholar
• Kölbl AC, Andergassen U, Jeschke U. The role of glycosylation in breast cancer metastasis and cancer control. Front Oncol. 2015 Oct 13;5:219. 08/26/received 09/24/accepted. PubMed PMID: PMC4602128.
   PubMed Web of Science ®Google Scholar
• Taparra K, Tran PT, Zachara NE. Hijacking the hexosamine biosynthetic pathway to promote EMT-mediated neoplastic phenotypes. Front Oncol. 2016 Apr 18;6:85. 02/22/received 03/27/accepted. PubMed PMID: PMC4834358.
   PubMed Web of Science ®Google Scholar
• Lau KS, Partridge EA, Grigorian A, et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 2007 Apr 6;129(1):123–134. PubMed PMID: 17418791; eng.
   PubMed Web of Science ®Google Scholar
• Kudelka MR, Ju T, Heimburg-Molinaro J, et al. Simple sugars to complex disease–mucin-type O-glycans in cancer. Adv Cancer Res. 2015;126:53–135. PubMed PMID: 25727146; PubMed Central PMCID: PMCPMC5812724. eng.
   PubMed Web of Science ®Google Scholar
• David L, Nesland JM, Clausen H, et al. Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn and T) in gastric mucosa, carcinomas and metastases. APMIS Suppl. 1992;27:162–172. PubMed PMID: 1520525; eng.
   PubMedGoogle Scholar
• Drake RR, Powers TW, Jones EE, et al. MALDI Mass spectrometry imaging of N-linked glycans in cancer tissues. Adv Cancer Res. 2017;134:85–116. PubMed PMID: 28110657; PubMed Central PMCID: PMCPMC6020705. eng.
   PubMed Web of Science ®Google Scholar
• Gill DJ, Chia J, Senewiratne J, et al. Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. J Cell Biol. 2010 May 31;189(5):843–858. PubMed PMID: 20498016; PubMed Central PMCID: PMCPMC2878949. eng.
   PubMed Web of Science ®Google Scholar
• Berois N, Gattolliat CH, Barrios E, et al. GALNT9 gene expression is a prognostic marker in neuroblastoma patients. Clin Chem. 2013 Jan;59(1):225–233. PubMed PMID: 23136245; eng.
   PubMed Web of Science ®Google Scholar
• Itzkowitz S, Kjeldsen T, Friera A, et al. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology. 1991 Jun;100(6):1691–1700. PubMed PMID: 1850375; eng.
   PubMed Web of Science ®Google Scholar
• Powers TW, Holst S, Wuhrer M, et al. Two-dimensional N-glycan distribution mapping of hepatocellular carcinoma tissues by MALDI-imaging mass spectrometry [Article]. Biomolecules. 2015;5(4):2554–2572.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan P, Dabelsteen S, Madsen FB, et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):E4066–E4075. PubMed PMID: 25118277; PubMed Central PMCID: PMCPMC4191756. eng.
   PubMed Web of Science ®Google Scholar
• Reis CA, David L, Seixas M, et al. Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer. 1998 Aug 21;79(4):402–410. PubMed PMID: 9699534; eng.
   PubMed Web of Science ®Google Scholar
• Ricardo S, Marcos-Silva L, Pereira D, et al. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours. Mol Oncol. 2015 Feb;9(2):503–512. PubMed PMID: 25454345; PubMed Central PMCID: PMCPMC5528651. eng.
   PubMed Web of Science ®Google Scholar
• Sewell R, Backstrom M, Dalziel M, et al. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem. 2006 Feb 10;281(6):3586–3594. PubMed PMID: 16319059; eng.
   PubMed Web of Science ®Google Scholar
• Bhide GP, Colley KJ. Sialylation of N-glycans: mechanism, cellular compartmentalization and function [journal article]. Histochem Cell Biol. 2017 February 01;147(2):149–174.
   PubMed Web of Science ®Google Scholar
• Ciborowski P, Finn OJ. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clin Exp Metastasis. 2002;19(4):339–345. PubMed PMID: 12090474; eng.
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008 Sep 1;26(25):4063–4071. PubMed PMID: 18678838; PubMed Central PMCID: PMCPMC2654377. eng.
   PubMed Web of Science ®Google Scholar
• Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications [Review]. Nat Rev Cancer. 2015 Sep;15(9):540–555. print.
   PubMed Web of Science ®Google Scholar
• Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–260. PubMed PMID: 9597130; eng.
   PubMed Web of Science ®Google Scholar
• Au GH, Mejias L, Swami VK, et al. Quantitative assessment of Tn antigen in breast tissue micro-arrays using CdSe aqueous quantum dots. Biomaterials. 2014 Mar;35(9):2971–2980. PubMed PMID: 24411673; eng.
   PubMed Web of Science ®Google Scholar
• Girling A, Bartkova J, Burchell J, et al. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer. 1989 Jun 15;43(6):1072–1076. PubMed PMID: 2471698; eng.
   PubMed Web of Science ®Google Scholar
• Burchell J, Poulsom R, Hanby A, et al. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology. 1999 Dec;9(12):1307–1311. PubMed PMID: 10561455; eng.
   PubMed Web of Science ®Google Scholar
• Lloyd KO, Burchell J, Kudryashov V, et al. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem. 1996 Dec 27;271(52):33325–33334. PubMed PMID: 8969192; eng.
   PubMed Web of Science ®Google Scholar
• Muller S, Alving K, Peter-Katalinic J, et al. High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells. J Biol Chem. 1999 Jun 25;274(26):18165–18172. PubMed PMID: 10373415; eng.
   PubMed Web of Science ®Google Scholar
• Julien S, Ivetic A, Grigoriadis A, et al. Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Res. 2011 Dec 15;71(24):7683–7693. PubMed PMID: 22025563; eng.
   PubMed Web of Science ®Google Scholar
• Beatson R, Maurstad G, Picco G, et al. The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, are expressed in COSMC wild-type cells and bind the C-Type Lectin MGL. PloS One. 2015;10(5):e0125994. PubMed PMID: 25951175; PubMed Central PMCID: PMCPMC4423978. eng.
   PubMed Web of Science ®Google Scholar
• Gill DJ, Tham KM, Chia J, et al. Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness. Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):E3152–E3161. PubMed PMID: 23912186; PubMed Central PMCID: PMCPMC3752262. eng.
   PubMed Web of Science ®Google Scholar
• Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat Rev Immunol. 2008 Nov;8(11):874–887. PubMed PMID: 18846099; PubMed Central PMCID: PMCPMC2768770. eng.
   PubMed Web of Science ®Google Scholar
• Cazet A, Julien S, Bobowski M, et al. Tumour-associated carbohydrate antigens in breast cancer. BCR. 2010;12(3):204. PubMed PMID: 20550729.
   PubMed Web of Science ®Google Scholar
• Dall’Olio F, Chiricolo M. Sialyltransferases in cancer. Glycoconj J. 2001 Nov-Dec;18(11–12):841–850. PubMed PMID: 12820717; eng.
   PubMed Web of Science ®Google Scholar
• Harduin-Lepers A, Krzewinski-Recchi MA, Colomb F, et al. Sialyltransferases functions in cancers. Front Biosci (Elite Ed). 2012 Jan 1;4:499–515. PubMed PMID: 22201891; eng.
   PubMedGoogle Scholar
• Baldus SE, Zirbes TK, Monig SP, et al. Histopathological subtypes and prognosis of gastric cancer are correlated with the expression of mucin-associated sialylated antigens: sialosyl-Lewis(a), Sialosyl-Lewis(x) and sialosyl-Tn. Tumour Biol. 1998;19(6):445–453. PubMed PMID: 9817972; eng.
   PubMedGoogle Scholar
• Amado M, Carneiro F, Seixas M, et al. Dimeric sialyl-Le(x) expression in gastric carcinoma correlates with venous invasion and poor outcome. Gastroenterology. 1998 Mar;114(3):462–470. PubMed PMID: 9496936; eng.
   PubMed Web of Science ®Google Scholar
• Rosen SD, Bertozzi CR. The selectins and their ligands. Curr Opin Cell Biol. 1994 Oct;6(5):663–673. PubMed PMID: 7530461; eng.
   PubMed Web of Science ®Google Scholar
• Haxho F, Neufeld RJ, Szewczuk MR. Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis. Oncotarget. 2016;7(26):40860–40881. PubMed PMID: 27029067; eng.
   PubMedGoogle Scholar
• Haxho F, Allison S, Alghamdi F, et al. Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma. Breast Cancer (Dove Med Press). 2014;6:191–203. PubMed PMID: 25525387; PubMed Central PMCID: PMCPMC4266271. eng.
   PubMedGoogle Scholar
• Beatson R, Tajadura-Ortega V, Achkova D, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016 Nov;17(11):1273–1281. PubMed PMID: 27595232; PubMed Central PMCID: PMCPMC5257269. eng.
   PubMed Web of Science ®Google Scholar
• Hudak JE, Canham SM, Bertozzi CR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. 2014 Jan;10(1):69–75. PubMed PMID: 24292068; PubMed Central PMCID: PMCPMC3893890. eng.
   PubMed Web of Science ®Google Scholar
• Jandus C, Boligan KF, Chijioke O, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest. 2014 Apr;124(4):1810–1820. PubMed PMID: 24569453; PubMed Central PMCID: PMCPMC3973073. eng.
   PubMed Web of Science ®Google Scholar
• Laubli H, Pearce OM, Schwarz F, et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14211–14216. PubMed PMID: 25225409; PubMed Central PMCID: PMCPMC4191788. eng.
   PubMed Web of Science ®Google Scholar
• Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014 Oct;14(10):653–666. PubMed PMID: 25234143; PubMed Central PMCID: PMCPMC4191907. eng.
   PubMed Web of Science ®Google Scholar
• Xiao H, Woods EC, Vukojicic P, et al. Precision glycocalyx editing as a strategy for cancer immunotherapy. Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10304–10309. PubMed PMID: 27551071; PubMed Central PMCID: PMCPMC5027407. eng.
   PubMed Web of Science ®Google Scholar
• Ma X, Dong W, Su Z, et al. Functional roles of sialylation in breast cancer progression through miR-26a/26b targeting ST8SIA4 [Original Article]. Cell Death Dis. 2016 Dec 29;7:e2561. online. https://www.nature.com/articles/cddis2016427#supplementary-information
   PubMed Web of Science ®Google Scholar
• Tian Y, Esteva FJ, Song J, et al. Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry. Mol Cell Proteomics. 2012;11:M111.011403.
   Web of Science ®Google Scholar
• Brockhausen I. Mucin‐type O‐glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 2006;7(6):599–604.
   PubMed Web of Science ®Google Scholar
• Brockhausen I, Yang J-M, Burchell J, et al. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem. 1995;233(2):607–617.
   PubMedGoogle Scholar
• Picco G, Julien S, Brockhausen I, et al. Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology. 2010;20(10):1241–1250.
   PubMed Web of Science ®Google Scholar
• Videira PA, Correia M, Malagolini N, et al. ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer. 2009 Oct 07;9(1):357.
   PubMedGoogle Scholar
• Ren D, Jia L, Li Y, et al. ST6GalNAcII mediates the invasive properties of breast carcinoma through PI3K/Akt/NF-kappaB signaling pathway. IUBMB Life. 2014 Apr;66(4):300–308. PubMed PMID: 24756995; eng.
   PubMed Web of Science ®Google Scholar
• Nguyen K, Yan Y, Yuan B, et al. ST8SIA1 regulates tumor growth and metastasis in TNBC by activating the FAK-AKT-mTOR signaling pathway. Mol Cancer Ther. 2018 Dec;17(12):2689–2701. PubMed PMID: 30237308; PubMed Central PMCID: PMCPMC6279518. eng.
   PubMed Web of Science ®Google Scholar
• Orsi G, Barbolini M, Ficarra G, et al. GD2 expression in breast cancer. Oncotarget. 2017 May 9;8(19):31592–31600. PubMed PMID: 28415563; PubMed Central PMCID: PMCPMC5458232. eng.
   PubMedGoogle Scholar
• Becker DJ, Lowe JB. Fucose: biosynthesis and biological function in mammals. Glycobiology. 2003;13(7):41R–53R.
   PubMed Web of Science ®Google Scholar
• Rosato FE, Seltzer M, Mullen J, et al. Serum fucose in the diagnosis of breast cancer. Cancer. 1971;28(6):1575–1579.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Kuroki Y, Ohtsubo K, et al. Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. Carbohydr Res. 2009 Aug 17;344(12):1387–1390.
   PubMed Web of Science ®Google Scholar
• Wang X, Gu J, Ihara H, et al. Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem. 2006 Feb 3;281(5):2572–2577. PubMed PMID: 16316986; eng.
   PubMed Web of Science ®Google Scholar
• Carrascal MA, Silva M, Ramalho JS, et al. Inhibition of fucosylation in human invasive ductal carcinoma reduces E-selectin ligand expression, cell proliferation, and ERK1/2 and p38 MAPK activation. Mol Oncol. 2018 May;12(5):579–593. PubMed PMID: 29215790; PubMed Central PMCID: PMCPMC5928367. eng.
   PubMed Web of Science ®Google Scholar
• Tu C-F, Wu M-Y, Lin Y-C, et al. FUT8 promotes breast cancer cell invasiveness by remodeling TGF-β receptor core fucosylation. BCR. 2017;19(1):111. PubMed PMID: 28982386; eng.
   PubMedGoogle Scholar
• Koh YW, Lee HJ, Ahn JH, et al. Expression of Lewis X is associated with poor prognosis in triple-negative breast cancer. Am J Clin Pathol. 2013 Jun;139(6):746–753. PubMed PMID: 23690116; eng.
   PubMed Web of Science ®Google Scholar
• Brooks SA, Leathem AJ. Expression of the CD15 antigen (Lewis x) in breast cancer. Histochem J. 1995 Sep;27(9):689–693. PubMed PMID: 8557532; eng.
   PubMedGoogle Scholar
• Yue L, Han C, Li Z, et al. Fucosyltransferase 8 expression in breast cancer patients: A high throughput tissue microarray analysis. Histol Histopathol. 2016 May;31(5):547–555. PubMed PMID: 26596733; eng.
   PubMed Web of Science ®Google Scholar
• Kailemia MJ, Park D, Lebrilla CB. Glycans and glycoproteins as specific biomarkers for cancer [journal article]. Anal Bioanal Chem. 2017 Jan 01;409(2):395–410.
   PubMed Web of Science ®Google Scholar
• Chang MC, Souter LH, Kamel-Reid S, et al. Clinical utility of multigene profiling assays in early-stage breast cancer. Curr Oncol. 2017 Oct;24(5):e403–e422. PubMed PMID: 29089811; PubMed Central PMCID: PMCPMC5659165. eng.
   PubMed Web of Science ®Google Scholar
• Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. BCR. 2006;8(3):R25. PubMed PMID: 16737553; PubMed Central PMCID: PMCPMC1557737. eng.
   PubMed Web of Science ®Google Scholar
• Penault-Llorca FM, Filleron T, Asselain B, et al. Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: results from PACS01 trial. J Clin Oncol. 2014 May 20;32(15_suppl):11052.
   Web of Science ®Google Scholar
• Xin L, Liu Y-H, Martin TA, et al. The era of multigene panels comes? The clinical utility of oncotype DX and MammaPrint. World J Oncol. 2017 May 04;8(2):34–40. 03/29/accepted. PubMed PMID: PMC5649994.
   PubMedGoogle Scholar
• Apuri S. Neoadjuvant and adjuvant therapies for breast cancer. South Med J. 2017 Oct;110(10):638–642. PubMed PMID: 28973704; eng.
   PubMed Web of Science ®Google Scholar
• Sokolenko AP, Imyanitov EN. Molecular diagnostics in clinical oncology. Front Mol Biosci. 2018;5:76. PubMed PMID: 30211169; PubMed Central PMCID: PMCPMC6119963. eng.
   PubMed Web of Science ®Google Scholar
• de Leoz MLA, Young LJT, An HJ, et al. High-Mannose glycans are elevated during breast cancer progression. Mol Cell Proteomics. 2011 Nov 19;10(1):M110.002717. 07/06/received 11/15/revised. PubMed PMID: PMC3013453.
   PubMed Web of Science ®Google Scholar
• Pierce A, Saldova R, Abd Hamid UM, et al. Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients. Glycobiology. 2010;20(10):1283–1288.
   PubMed Web of Science ®Google Scholar
• Jia Y, Chen Y, Wang Q, et al. Exosome: emerging biomarker in breast cancer. Oncotarget. 2017 Jun 20;8(25):41717–41733. PubMed PMID: 28402944; PubMed Central PMCID: PMCPMC5522217. eng.
   PubMed Web of Science ®Google Scholar
• Ruhaak LR, Xu G, Li Q, et al. Mass spectrometry approaches to glycomic and glycoproteomic analyses. Chem Rev. 2018 Sep 12;118(17):7886–7930. PubMed PMID: 29553244; eng.
   PubMed Web of Science ®Google Scholar
• Hill JJ, Tremblay TL, Fauteux F, et al. Glycoproteomic comparison of clinical triple-negative and luminal breast tumors. J Proteome Res. 2015 Mar 6;14(3):1376–1388. PubMed PMID: 25658377; eng.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li XJ, Martin DB, et al. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003 Jun;21(6):660–666. PubMed PMID: 12754519; eng.
   PubMed Web of Science ®Google Scholar
• Powers TW, Neely BA, Shao Y, et al. MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin embedded clinical tissue blocks and tissue microarrays. PloS One. 2014;9(9):e106255. PubMed PMID: 25184632; PubMed Central PMCID: PMCPMC4153616. eng.
   PubMed Web of Science ®Google Scholar
• Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med (Lausanne). 2017;4:227. PubMed PMID: 29276709; eng.
   PubMed Web of Science ®Google Scholar
• Wang J, Ma Z, Carr SA, et al. Proteome profiling outperforms transcriptome profiling for coexpression based gene function prediction. Mol Cell Proteomics. 2017 Jan;16(1):121–134. PubMed PMID: 27836980; PubMed Central PMCID: PMCPMC5217778. eng.
   PubMed Web of Science ®Google Scholar
• Johansson HJ, Socciarelli F, Vacanti NM, et al. Breast cancer quantitative proteome and proteogenomic landscape. Nat Commun. 2019 Apr 08;10(1):1600.
   PubMed Web of Science ®Google Scholar
• Matsunuma R, Chan DW, Kim B-J, et al. DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Nat Acad Sci. 2018;115(51):E11978–E11987.
   PubMed Web of Science ®Google Scholar
• Griffith OL, Spies NC, Anurag M, et al. The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun. 2018 Sep 04;9(1):3476.
   PubMedGoogle Scholar
• Mertins P, Mani DR, Ruggles KV, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016 Jun 2;534(7605):55–62. PubMed PMID: 27251275; PubMed Central PMCID: PMCPMC5102256. eng.
   PubMed Web of Science ®Google Scholar
• Mardamshina M, Geiger T. Next-generation proteomics and its application to clinical breast cancer research. Am J Pathol. 2017;187(10):2175–2184.
   PubMed Web of Science ®Google Scholar
• Banazadeh A, Veillon L, Wooding KM, et al. Recent advances in mass spectrometric analysis of glycoproteins. Electrophoresis. 2017 Jan;38(1):162–189. PubMed PMID: 27757981; PubMed Central PMCID: PMCPMC5221507. eng.
   PubMed Web of Science ®Google Scholar
• Hu H, Khatri K, Klein J, et al. A review of methods for interpretation of glycopeptide tandem mass spectral data. Glycoconj J. 2016 Jun;33(3):285–296. PubMed PMID: 26612686; PubMed Central PMCID: PMCPMC4882288. eng.
   PubMed Web of Science ®Google Scholar
• Ruhaak LR, Xu G, Li Q, et al. Mass spectrometry approaches to glycomic and glycoproteomic analyses. Chem Rev. 2018;118:7886–7930.
   PubMed Web of Science ®Google Scholar
• Sanda M, Zhang L, Edwards NJ, et al. Site-specific analysis of changes in the glycosylation of proteins in liver cirrhosis using data-independent workflow with soft fragmentation. Anal Bioanal Chem. 2017 Jan;409(2):619–627. PubMed PMID: 27822650; PubMed Central PMCID: PMCPMC5370557. eng.
   PubMed Web of Science ®Google Scholar
• Thaysen-Andersen M, Packer NH. Advances in LC–MS/MS-based glycoproteomics: getting closer to system-wide site-specific mapping of the N- and O-glycoproteome. Biochim Biophys Acta Proteins Proteom. 2014 Sep 01;1844(9):1437–1452.
   PubMed Web of Science ®Google Scholar
• Klein J, Carvalho L, Zaia J. Application of network smoothing to glycan LC-MS profiling. Bioinformatics. 2018 Oct 15;34(20):3511–3518. PubMed PMID: 29790907; eng.
   PubMed Web of Science ®Google Scholar
• Vos DRN, Jansen I, Lucas M, et al. Strategies for managing multi-patient 3D mass spectrometry imaging data. J Proteomics. 2019 Feb 20;193:184–191. PubMed PMID: 30343012; eng.
   PubMed Web of Science ®Google Scholar
• Liang Y, Wang F, Zhang P, et al. Development of a framework for large scale three-dimensional pathology and biomarker imaging and spatial analytics. AMIA Jt Summits Transl Sci Proc. 2017;2017:75–84. PubMed PMID: 28815110; eng.
   PubMedGoogle Scholar
• Gray CJ, Thomas B, Upton R, et al. Applications of ion mobility mass spectrometry for high throughput, high resolution glycan analysis. Biochim Biophys Acta. 2016 Aug;1860(8):1688–1709. PubMed PMID: 26854953; eng.
   PubMed Web of Science ®Google Scholar
• Fenn LS, McLean JA. Structural separations by ion mobility-MS for glycomics and glycoproteomics. Methods Mol Biol. 2013;951:171–194. PubMed PMID: 23296531; PubMed Central PMCID: PMCPMC5102027. eng.
   PubMedGoogle Scholar
• Skraskova K, Claude E, Jones EA, et al. Enhanced capabilities for imaging gangliosides in murine brain with matrix-assisted laser desorption/ionization and desorption electrospray ionization mass spectrometry coupled to ion mobility separation. Methods. 2016 Jul 15;104:69–78. PubMed PMID: 26922843; eng.
   PubMed Web of Science ®Google Scholar
• Hinneburg H, Korac P, Schirmeister F, et al. Unlocking cancer glycomes from histopathological Formalin-fixed and Paraffin-embedded (FFPE) tissue microdissections. Mol Cell Proteomics. 2017 Apr;16(4):524–536. PubMed PMID: 28122943; PubMed Central PMCID: PMCPMC5383776. eng.
   PubMed Web of Science ®Google Scholar
• Malaker SA, Pedram K, Ferracane MJ, et al. The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7278–7287. PubMed PMID: 30910957; PubMed Central PMCID: PMCPMC6462054. eng.
   PubMed Web of Science ®Google Scholar
• Yang W, Ao M, Hu Y, et al. Mapping the O-glycoproteome using site-specific extraction of O-linked glycopeptides (EXoO). Mol Syst Biol. 2018 Nov 20;14(11):e8486. PubMed PMID: 30459171; PubMed Central PMCID: PMCPMC6243375. eng.
   PubMed Web of Science ®Google Scholar
• Tzanakakis G, Neagu M, Tsatsakis A, et al. Proteoglycans and immunobiology of cancer-therapeutic implications. Front Immunol. 2019;10:875. PubMed PMID: 31068944; PubMed Central PMCID: PMCPMC6491844. eng.
   PubMed Web of Science ®Google Scholar
• Soliman NA, Yussif SM, Shebl AM. Syndecan-1 could be added to hormonal receptors and HER2/neu in routine assessment of invasive breast carcinoma, relation of its expression to prognosis and clinicopathological parameters. Pathol Res Pract. 2019 May;215(5):977–982. PubMed PMID: 30738694; eng.
   PubMed Web of Science ®Google Scholar
• Vikas P, Borcherding N, Zhang W. The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Manag Res. 2018;10:6823–6833. PubMed PMID: 30573992; eng.
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016 Jul 20;34(21):2460–2467. PubMed PMID: 27138582; eng.
   PubMed Web of Science ®Google Scholar
• Adams S, Loi S, Toppmeyer D, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): preliminary data from KEYNOTE-086 cohort B. J Clin Oncol. 2017 May 20;35(15_suppl):1088.
   Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. J Clin Oncol. 2017 May 20;35(15_suppl):1008.
   Google Scholar
• Li C-W, Lim S-O, Chung EM, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33(2):187–201.e10.
   PubMed Web of Science ®Google Scholar
• Salatino M, Girotti MR, Rabinovich GA. Glycans pave the way for immunotherapy in triple-negative breast cancer. Cancer Cell. 2018;33(2):155–157.
   PubMed Web of Science ®Google Scholar